TRIB - トリニティ・バイオテック （Trinity Biotech plc）

Trinity Biotech plc (NASDAQ:NASDAQ:TRIB) Q1 2022 Earnings Conference Call June 30, 2022, 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan O’Caoimh - Chairman and Chief…

Trinity Biotech press release (TRIB): Q1 GAAP EPADS of -50c.Revenue of $18.78M (-26.6% Y/Y) misses by $1.22M.

DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022.

Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN

Trinity Biotech (TRIB) said on Friday it had achieved the European CE Mark or approval for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals…

Trinity Biotech Plc - ADR (TRIB) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $27M. The stock is currently down 8.4% year-to-date, down 67.2% over the past 12 months, and down 80.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3.0% The company's stock price performance over the past 12 months lags the peer average by 511.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Trinity Biotech Plc - ADR (TRIB) shares closed 5.1% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently down 3.5% year-to-date, down 67.9% over the past 12 months, and down 79.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.1% lower than its 5-day moving average, 14.9% lower than its 20-day moving average, and 33.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -49.2% The company's stock price performance over the past 12 months lags the peer average by 750.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

TheStreet downgraded shares of Trinity Biotech (NASDAQ:TRIB) from a c- rating to a d- rating in a report published on Monday, TheStreetRatingsTable reports. TRIB stock opened at $1.58 on Monday. The companys 50-day simple moving average is $1.88 and its 200 day simple moving average is $2.26. Trinity Biotech has a 52 week low of []

DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the Company), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Companys subsidiary, Trinity Biotech Investment Limited (the Notes), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.

Trinity Biotech Plc - ADR (TRIB) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $27M. The stock is currently down 8.4% year-to-date, down 67.2% over the past 12 months, and down 80.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3.0% The company's stock price performance over the past 12 months lags the peer average by 511.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Trinity Biotech Plc - ADR (TRIB) shares closed 5.1% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently down 3.5% year-to-date, down 67.9% over the past 12 months, and down 79.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.1% lower than its 5-day moving average, 14.9% lower than its 20-day moving average, and 33.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -49.2% The company's stock price performance over the past 12 months lags the peer average by 750.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

TheStreet downgraded shares of Trinity Biotech (NASDAQ:TRIB) from a c- rating to a d- rating in a report published on Monday, TheStreetRatingsTable reports. TRIB stock opened at $1.58 on Monday. The companys 50-day simple moving average is $1.88 and its 200 day simple moving average is $2.26. Trinity Biotech has a 52 week low of []

DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the Company), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Companys subsidiary, Trinity Biotech Investment Limited (the Notes), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.